Table 3.
Registered (n = 179) | First meeting (n = 165) | Genetic testing |
|||||
---|---|---|---|---|---|---|---|
alla(n = 167) | no pathogenic variantsa, b(n = 134) | BRCA1 (n = 19) | BRCA2 (n = 9) | other pathogenic variantsc(n = 5) | |||
Before BC diagnosis | |||||||
<–15 years | 11 (6.1) | 6 (3.6) | 4 (2.4) | 0 | 3 (15.8) | 1 (11.1) | 0 |
After BC diagnosis | |||||||
0–1 years | 73 (40.8) | 73 (44.2) | 53 (31.7) | 42 (31.3) | 6 (31.6) | 4 (44.4) | 1 (20.0) |
1–2 years | 39 (21.8) | 42 (25.5) | 52 (31.1) | 46 (34.3) | 3 (15.8) | 2 (22.2) | 1 (20.0) |
2–3 years | 12 (6.7) | 12 (7.3) | 18 (10.8) | 16 (11.9) | 1 (5.3) | 1 (11.1) | 0 |
3–4 years | 7 (3.9) | 6 (3.6) | 10 (6.0) | 6 (4.5) | 2 (10.5) | 0 | 2 (40.0) |
4–5 years | 5 (2.8) | 4 (2.4) | 4 (2.4) | 3 (2.2) | 1 (5.3) | 0 | 0 |
5–10 years | 21 (11.7) | 16 (9.7) | 18 (10.8) | 15 (11.2) | 1 (5.3) | 1 (11.1) | 1 (20.0) |
10–15 years | 11 (6.1) | 6 (3.6) | 7 (4.2) | 6 (4.5) | 1 (5.3) | 0 | 0 |
Missing | 0 | 0 | 1 (0.6) | 0 | 1 (5.3) | 0 | 0 |
Data are presented as n (%).
Of which 2 BC patients underwent genetic testing without being registered at the Oncogenetic Clinic in Lund.
Genetic testing without findings, including variants of uncertain significance.
Positive for a germline pathogenic variant in TP53 (n = 3) or CHEK2 (n = 2).